Product Description
Merck was developing mk-3281, an oral HCV-NS5B Inhibitor for Hepatitis C. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00635804)
Mechanisms of Action: HCV-NS5B Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatitis C|Hepatitis A
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00635804 |
MK-3281-002 | P1 |
Completed |
Hepatitis A|Hepatitis C |
2009-12-22 |
2022-05-04 |
Recent News Events
Date |
Type |
Title |
|---|